ULK1 has canonical and non-canonical functions impacting metastatic progression and treatment of advanced ovarian cancer
Year: 2026
Type: dissertation
Abstract: Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy, largely due to late-stage diagnosis, peritoneal metastasis, and therapeutic resistance. EOC commonly disseminates as multicellular spheroids, which survive in ascites, resist detachment-associated stress, and seed secondary tumours. Autophagy supports spheroid survival, yet the contribution of unc-51-like kinase 1 (ULK1), a canonical autophagy-initiating kinase with emerging non-canonical functions, remains incompletely understood. This thesis investigates the hypothesis that ULK1 has canonical and non-canonical functions impacting the metastatic progression and treatment of advanced ovarian cancer. Using CRISPR/Cas9-mediated ULK1 knockout models in OVCAR8, HEYA8, and ES2 EOC cells, I demonstrated that ULK1 loss disrupts autophagy in EOC spheroids, reduces spheroid viability, increases apoptosis, impairs organoid growth, and diminishes mesothelial clearance. In vivo, ULK1-deficient cells formed fewer tumours and showed reduced metastatic burden, establishing ULK1 as a functional driver of EOC progression. Proteomic analysis of OVCAR8 spheroids revealed that ULK1 loss alters MEK-MAPK, PI3K-AKT-mTOR, apoptosis, vesicle trafficking, and mitochondrial pathways. Although ULK1 loss did not enhance chemotherapy-induced cell killing, it increased sensitivity to MEK and mTOR inhibition. Clinical dataset analyses showed that high ULK1 expression is associated with poorer survival and elevated expression in metastatic disease, while patient-derived organoids demonstrated heterogeneous responses to ULK1-, MEK-, and mTOR-targeted therapies. Building on these findings, I investigated ULK1-dependent mitochondrial regulation. ULK1 loss either promoted or protected against mitochondrial degradation depending on cellular context, and these effects were independent of canonical autophagic machinery. ULK1 deficiency also reduced oxidative phosphorylation complex proteins and the glycolytic enzyme HK2 spheroids, while Seahorse ATP-rate assays revealed divergent bioenergetic rewiring across EOC models. Finally, transcriptomic profiling across adherent and spheroid conditions identified spheroid culture as a context that reveals conserved ULK1-dependent programs. Integration of proteomic and RNAseq analysis nominated reduced MYC target signaling as a conserved feature of ULK1-deficient spheroids, and MYC knockdown phenocopied ULK1 loss by reducing spheroid viability. Together, this thesis identifies ULK1 as a context-dependent regulator of EOC spheroid survival, mitochondrial adaptation, MYC-associated transcriptional programs, and metastatic progression. These findings support ULK1 as a therapeutic target in advanced EOC, while emphasizing that it’s context-dependent functions that may be exploited therapeutically.
Author: Webb, Jack Douglas
Institution: Western University
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Keywords: ULK1, epithelial ovarian cancer, autophagy, multicellular spheroids, peritoneal carcinomatosis, patient-derived organoids, MEK inhibition, mTOR inhibition, mitochondrial degradation, oxidative phosphorylation, glycolysis, MYC signaling, apoptosis, mesothelial clearance, treatment resistance, prognostic factors
Open Access status: green
OpenAlex ID: W7215006279
